CLINICAL USE


Counteract anticoagulant effect of heparin

DOSE IN NORMAL RENAL FUNCTION

Depends on time since stopping IV/subcutaneous heparin and dose of heparin given

PHARMACOKINETICS

  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Approx 4500
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :1
  • %Excreted unchanged in urine &nbsp &nbsp : No data
  • Volume of distribution (L/kg) &nbsp &nbsp &nbsp :12.3 litres
  • half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :7.4 minutes/–

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Unknown dialysability. Dose as in normal renal function
  • HDF/high flux &nbsp :Unknown dialysability. Dose as in normal renal function
  • CAV/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs
  • None known

    ADMINISTRATION

    Reconstition

    Route

    Rate of Administration

    5 mg/minute

    Comments

    OTHER INFORMATION

    Counteracting the anticoagulant effect of heparin during extra-corporeal treatments requires approximately 1.5 mg protamine per 100 IU heparinMost clinicians recommend a dose of 1–1.5 mg protamine sulphate for each 100 units heparin given depending on the length of time since heparin administrationMay be used topically to stop bleeding fistulae